Ken Griffin Genfit S.A. Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.34 - $4.04 $56,222 - $68,005	16,833 New	16,833 $59,000
Q1 2023 May 15, 2023	SELL	$3.93 - $4.69 $7,753 - $9,253	-1,973 Reduced 9.15%	19,592 $80,000
Q4 2022 Feb 14, 2023	SELL	$3.53 - $4.39 $48,551 - $60,380	-13,754 Reduced 38.94%	21,565 $94,000
Q3 2022 Nov 14, 2022	BUY	$3.26 - $4.86 $74,282 - $110,739	22,786 Added 181.81%	35,319 $129,000

49.2K

Ticker GNFT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,815,500
Market Cap $284M
Description
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.